Takeda and Sucampo enter into global licensing agreement for AMITIZA(R) (lubiprostone)
Sucampo and Takeda announced a global license, development, commercialization and supply agreement for AMITIZAź (lubiprostone). Takeda expanded its exclusive rights beyond the U.S. and Canada to further develop and commercialize AMITIZA in all global markets. October 21, 2014